TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1534089

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg monthly combined with oral MPA 15 mg daily for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Goserelin alone for the initial 3 months, followed by combined treatment for 3 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two years after completion
Number of subjects: 20
Study: 3728925

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ketamine anaesthesia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison between Halothane and Ketamine
Number of subjects: 19
Study: 30852029

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 462

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Prediabetes defined by IFG/IGT
Number of subjects: 462

Group type: COMPARATOR
Intervention: Prediabetes defined by isolated-HbA1c
Number of subjects: 462

Group type: COMPARATOR
Intervention: Non-Prediabetics
Number of subjects: 462
Study: 30133718

Group type: COMPARATOR
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both GBR and CTG
Number of subjects: 42
Study: 26546392

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (Ropi group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine (Levo group)
Number of subjects: 34
Study: 24053621

Group type: EXPERIMENTAL
Intervention: Prostate biopsy after a positive screen
Number of subjects: 37435

Group type: COMPARATOR
Intervention: Control group (no biopsy after a negative screen)
Number of subjects: 37435

Group type: EXPERIMENTAL
Intervention: Negative biopsy
Number of subjects: 37435

Group type: EXPERIMENTAL
Intervention: History of prostate enlargement or inflammation
Number of subjects: 37435

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 37435

Group type: EXPERIMENTAL
Intervention: Repeat biopsy
Number of subjects: 37435
Study: 22871243

Group type: EXPERIMENTAL
Intervention: Prebiotic formula (PF)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 74
Study: 21181026

Group type: EXPERIMENTAL
Intervention: Single dose ROM Therapy (rifampin, ofloxacin, minocycline)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Single dose ROM Therapy
Number of subjects: 54
Study: 18211994

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.3% and 0.5%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (15% and 25%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol (approximately 80 mg per 100 ml)
Number of subjects: 0
Study: 16940700

Group type: EXPERIMENTAL
Intervention: Dietary intervention group consuming an average of 371.4 g/day of Okinawan vegetables for 14 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group avoiding Okinawan vegetables
Number of subjects: 56
Study: 14584229

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care programme provided by community pharmacists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal services provided at control sites
Number of subjects: 0
Study: 11173715

Group type: EXPERIMENTAL
Intervention: Acute exercise (submaximal and moderate exercise bout)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physical training (8 week program of aerobic exercise at 75% VO(2) peak, 45 min, twice a week and intermittent exercise once a week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 9098873

Group type: EXPERIMENTAL
Intervention: Understanding of medication directions
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Age 80 years or older
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 117
Study: 1490224

Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3885889

Group type: EXPERIMENTAL
Intervention: Hypocaloric liquid formula diet + glipizide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypocaloric liquid formula diet alone
Number of subjects: 20
Study: 31315375

Group type: EXPERIMENTAL
Intervention: SKT-M
Number of subjects: 121

Group type: COMPARATOR
Intervention: AVLT-H
Number of subjects: 121
Study: 29354672

Group type: COMPARATOR
Intervention: Low flow oxygen (LFO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heated humidified high flow air via nasal cannula (HFNC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (CTRL; no therapy)
Number of subjects: 32
Study: 24770948

Group type: EXPERIMENTAL
Intervention: Options for Health training and supervision (53 hours)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 91
Study: 23906815

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIV) combined with conventional therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 44
Study: 21450995

Group type: EXPERIMENTAL
Intervention: AS03(A)‐adjuvanted single dose (3.75 μg hemagglutinin)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: AS03(A)‐adjuvanted double dose (3.75 μg hemagglutinin)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Nonadjuvanted single dose
Number of subjects: 395

Group type: COMPARATOR
Intervention: Nonadjuvanted double dose
Number of subjects: 395
Study: 19654532

Group type: EXPERIMENTAL
Intervention: Suture removal 1 month before PE
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Suture removal during PE
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 14
Study: 16723401

Group type: EXPERIMENTAL
Intervention: Increased training volume (from 8.0 (3.0) to 12.5 (3.9) hours/week)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Increased training volume
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 23
Study: 15191200

Group type: COMPARATOR
Intervention: 7-day triple therapy (rabeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., amoxycillin 1 g b.i.d.)
Number of subjects: 342

Group type: COMPARATOR
Intervention: 10-day triple therapy (rabeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., amoxycillin 1 g b.i.d.)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen (rabeprazole 20 mg b.i.d. + amoxycillin 1 g b.i.d. for 5 days, followed by rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + tinidazole 500 mg b.i.d. for 5 days)
Number of subjects: 342

Group type: COMPARATOR
Intervention: 7-day triple therapy
Number of subjects: 342

Group type: COMPARATOR
Intervention: 10-day triple therapy
Number of subjects: 342
Study: 11041467

Group type: EXPERIMENTAL
Intervention: Stripping procedures
Number of subjects: 57

Group type: COMPARATOR
Intervention: Urokinase (UK) infusion at 30,000 U/h via each port concurrently, total 250,000 U
Number of subjects: 57
Study: 9071622

Group type: EXPERIMENTAL
Intervention: Paromomycin ointment (15% paromomycin sulfate and 12% methylbenzothonium chloride in white soft paraffin) applied twice daily for 15 days.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ketoconazole 400 mg/day orally for 30 days (200 mg/day for patients below 12 years of age).
Number of subjects: 72
Study: 8405754

Group type: EXPERIMENTAL
Intervention: High protein diet (2.0 g/kg desirable weight per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moderate protein diet (0.8 g/kg desirable weight per day)
Number of subjects: 12
Study: 3805711

Group type: EXPERIMENTAL
Intervention: I.R.S. 19 (intranasal spray), administered twice a day for 20 days, mean spraying period of 34 days.
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo, administered twice a day for 20 days, mean spraying period of 34 days.
Number of subjects: 825
Study: 30516713

Group type: EXPERIMENTAL
Intervention: TX-001HR (17β-estradiol/progesterone)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study: 28765801

Group type: EXPERIMENTAL
Intervention: Laminoplasty
Number of subjects: 70

Group type: COMPARATOR
Intervention: Laminectomy with Fusion (LF)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Laminoplasty and Laminectomy with Fusion
Number of subjects: 70
Study: 25981049

Group type: EXPERIMENTAL
Intervention: 8Gy in a single fraction with DPBN (arm B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 16Gy in a single fraction with DPBN (arm C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 8Gy in a single fraction with conventionally planned radiotherapy (arm A)
Number of subjects: 45
Study: 24355961

Group type: EXPERIMENTAL
Intervention: 5% amlexanox oral paste applied 4 times a day for 6 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo paste applied for the same duration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5% amlexanox paste used for one whole year by 30 patients with increased frequency of ulcers
Number of subjects: 100
Study: 21226789

Group type: EXPERIMENTAL
Intervention: Neuroticism (1 SD increase)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Age (5 year increment)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Cognitive function (1 SD decrease in mental status exam score)
Number of subjects: 771
Study: 18646365

Group type: EXPERIMENTAL
Intervention: Mobile non-contact camera-based digital imaging system (DIS)
Number of subjects: 36
Study: 16569550

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 94

Group type: COMPARATOR
Intervention: No antiarrhythmic agent
Number of subjects: 94
Study: 12835081

Group type: EXPERIMENTAL
Intervention: Daclizumab (Group II, n=10)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin-Fresenius (ATG-F) (Group I, n=35)
Number of subjects: 45
Study: 10977398

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 0
Study: 9161237

Group type: EXPERIMENTAL
Intervention: Intradermal local anesthetic
Number of subjects: 39
Study: 2070385

Group type: EXPERIMENTAL
Intervention: 0.8% sodium monofluorophosphate (MFP) with 3% xylitol and 6% sorbitol
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 0.03% sodium fluoride with 3% xylitol and 6% sorbitol
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 0.8% MFP with 9% sorbitol
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 0.03% sodium fluoride with 9% sorbitol
Number of subjects: 284
Study: 6421082

Group type: EXPERIMENTAL
Intervention: Vaginal cream (0.5 mg estriol)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vaginal suppository (0.5 mg estriol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both preparations (vaginal cream and suppository)
Number of subjects: 8
Study: 30409792

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2 once per week or 175 mg/m2 every 2 weeks)
Number of subjects: 1881
Study: 29945674

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment from month 4 to month 12 after an observational period.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observational period (no treatment) from baseline to month 4.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Assessment of safety and efficacy through standardized digital photographs and physician/patient assessments.
Number of subjects: 50
Study: 27151605

Group type: EXPERIMENTAL
Intervention: Transfemoral access (TFA)
Number of subjects: 4033

Group type: COMPARATOR
Intervention: Transradial access (TRA)
Number of subjects: 4033
Study: 25230264

Group type: EXPERIMENTAL
Intervention: Triple-bundle (TB) ACL reconstruction
Number of subjects: 105

Group type: COMPARATOR
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 105
Study: 22310592

Group type: EXPERIMENTAL
Intervention: FK506E
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (FK506)
Number of subjects: 124
Study: 20202105

Group type: COMPARATOR
Intervention: Vardenafil
Number of subjects: 0
Study: 17700927

Group type: EXPERIMENTAL
Intervention: Pregnant women (n=69)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 69
Study: 16243994

Group type: EXPERIMENTAL
Intervention: succinylcholine (1 mg/kg; endotracheal intubation as soon as possible)
Number of subjects: 180

Group type: COMPARATOR
Intervention: rocuronium (0.6 mg/kg; endotracheal intubation 60 s after injection)
Number of subjects: 180
Study: 11851637

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Evra/Ortho Evra) applied on abdomen
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Evra/Ortho Evra) applied on buttock
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Evra/Ortho Evra) applied on arm
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Evra/Ortho Evra) applied on torso
Number of subjects: 37
Study: 10335722

Group type: EXPERIMENTAL
Intervention: Risedronate 30 mg daily for 2 months
Number of subjects: 123

Group type: COMPARATOR
Intervention: Etidronate 400 mg daily for 6 months
Number of subjects: 123
Study: 8951188

Group type: EXPERIMENTAL
Intervention: 50 mg or 200 mg oral doses of nefazodone (NEF) as single doses on Day 1 and multiple (twice daily) doses on Days 12-22.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple dosing of nefazodone (NEF).
Number of subjects: 20
Study: 1656039

Group type: EXPERIMENTAL
Intervention: Low sodium, low fat, high fibre diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: High fibre diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 196
Study: 7079156

Group type: EXPERIMENTAL
Intervention: Repetitive stress (expectation of severe pain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31786279

Group type: COMPARATOR
Intervention: Endocrine Treatment (ET) alone
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Endocrine Treatment (ET) + 70 Gy prostatic Radiation Therapy (RT)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Salvage RT (≥60 Gy) in ET patients
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Endocrine Treatment (ET) with salvage RT
Number of subjects: 875
Study: 31530202

Group type: EXPERIMENTAL
Intervention: Mature ovarian teratoma
Number of subjects: 5652

Group type: EXPERIMENTAL
Intervention: Uterine fibroids
Number of subjects: 5652

Group type: EXPERIMENTAL
Intervention: Pregestational hypothyroidism
Number of subjects: 5652
Study: 28842792

Group type: EXPERIMENTAL
Intervention: Inertial sensor measurements
Number of subjects: 30
Study: 26255208

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg, twice daily for 5 days
Number of subjects: 4283

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 4283

Group type: COMPARATOR
Intervention: Untreated asymptomatic bacteriuria-positive women
Number of subjects: 4283

Group type: COMPARATOR
Intervention: Asymptomatic bacteriuria-negative women
Number of subjects: 4283
Study: 24422605

Group type: EXPERIMENTAL
Intervention: Novel antenatal programme based on the Tourné psychosomatic approach (10 group sessions of 2 hours each)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard antenatal education (8 to 10 two-hour sessions focused on childbirth by obstetrical prophylaxis)
Number of subjects: 184
Study: 21398094

Group type: EXPERIMENTAL
Intervention: Adjunctive SAMe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 0
Study: 19404900

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 100 microg daily for 3 days
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 17224471

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril 10 mg PO), angiotensin II receptor blocker (losartan 100 mg PO, eprosartan 600 mg PO)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control subjects (n=82)
Number of subjects: 74
Study: 14962150

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 670
Study: 11130603

Group type: EXPERIMENTAL
Intervention: Gentle human touch (GHT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 9214246

Group type: EXPERIMENTAL
Intervention: Patients who discussed preferences for cardiopulmonary resuscitation (CPR)
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Patients who had not discussed preferences for CPR
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Patients who had not discussed and did not want to discuss preferences for CPR
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Factors associated with not wanting to discuss preferences for CPR
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Factors associated with wanting to discuss preferences for CPR but not doing so
Number of subjects: 1832
Study: 8264028

Group type: COMPARATOR
Intervention: Medical group (aspirin and optimal medical care)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Surgical group (carotid endarterectomy)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Patients with a history of congestive heart failure (CHF)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Patients with bilateral carotid artery stenosis
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Patients with intracranial vascular disease (ICVD)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Patients with two or three risk factors (diabetes, abnormal ECG results, claudication)
Number of subjects: 444
Study: 3710742

Group type: EXPERIMENTAL
Intervention: Metrizoate 150 mg I/ml
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Metrizoate 200 mg I/ml
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Ioxaglate 200 mg I/ml
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 229
Study: 3218859

Group type: EXPERIMENTAL
Intervention: Simple intervention to teach interviewing skills
Number of subjects: 0
Study: 31895796

Group type: EXPERIMENTAL
Intervention: Cinnamon (Cinnamomum verum) 3 grams per day for 90 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 30833371

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 28438923

Group type: EXPERIMENTAL
Intervention: Reduced-clavulanate A/C formulation (90 mg amoxicillin/3.2 mg clavulanate/kg/day for 10 days)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Reduced-clavulanate A/C formulation (80 mg amoxicillin/2.85 mg clavulanate/kg/day for 10 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard A/C regimen (90 mg amoxicillin/6.4 mg clavulanate/kg/day)
Number of subjects: 112
Study: 25557606

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 75

Group type: COMPARATOR
Intervention: No-stress protocol
Number of subjects: 75
Study: 23020935

Group type: EXPERIMENTAL
Intervention: Child age, swimming lessons, home equipment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Child age, sex, unstructured activity participation, MVPA%, parent confidence, home equipment, dance participation
Number of subjects: 76
Study: 22025143

Group type: EXPERIMENTAL
Intervention: Capecitabine (intermittent: 1,000 mg/m² twice daily for 14 of every 21 days; n = 107)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Capecitabine (continuous: 650 mg/m² twice daily for 21 of every 21 days; n = 107)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Capecitabine (both intermittent and continuous combined)
Number of subjects: 323

Group type: COMPARATOR
Intervention: CMF (oral cyclophosphamide 100 mg/m² days 1 to 14, intravenous methotrexate 40 mg/m² and fluorouracil 600 mg/m² on days 1 and 8 every 28 days; n = 109)
Number of subjects: 323
Study: 18420749

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 88
Study: 16445968

Group type: EXPERIMENTAL
Intervention: Type II RH
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Type III Nerve-sparing RH (NSRH)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Type III RH
Number of subjects: 110
Study: 12919004

Group type: EXPERIMENTAL
Intervention: Severe interval-training programs (4- and 8-week duration) in few-trained subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Severe interval-training programs (4- and 8-week duration) in well-trained subjects
Number of subjects: 13
Study: 11105539

Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% cream (regimen A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Flutrimazole 2% cream (regimen B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Flutrimazole 4% cream (regimen C)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo cream (regimen D)
Number of subjects: 124
Study: 8600432

Group type: EXPERIMENTAL
Intervention: Central retinal artery (CRA) blood flow velocity measurement using pulsed Doppler sonography
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Retinal microcirculation (flow omega-ret) measurement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Resistivity index (RI) as a marker of vessel rigidity
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Optic nerve head blood flow measurement
Number of subjects: 85
Study: 1404440

Group type: EXPERIMENTAL
Intervention: Conjoint format
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Individual format
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Group-oriented information
Number of subjects: 135
Study: 3890519

Group type: EXPERIMENTAL
Intervention: Topical treatment with 10% sulfacetamide sodium ophthalmic solution
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral erythromycin estolate (50 mg/kg/day)
Number of subjects: 51
Study: 29797676

Group type: EXPERIMENTAL
Intervention: BAS/TAC/EVR
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: rAGT/TAC/EVR
Number of subjects: 273

Group type: COMPARATOR
Intervention: BAS/TAC/MPS
Number of subjects: 273